TRCT
OMED

Tower Research Capital (TRC)’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Tower Research Capital (TRC)’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-17,025
Closed -$36K – 4820
2018
Q3 		$36K Buy
17,025
+11,734
+222% +$28.1K ﹤0.01% 1975
2018
Q2 		$12K Buy
5,291
+5,212
+6,597% +$15.2K ﹤0.01% 2720
2018
Q1 		$0 Buy
+79
New +$218 ﹤0.01% 4328
2017
Q4 		– Sell
-5,250
Closed -$24K – 4505
2017
Q3 		$24K Sell
5,250
-6,240
-54% -$25.3K ﹤0.01% 2635
2017
Q2 		$38K Buy
11,490
+8,099
+239% +$33.6K ﹤0.01% 896
2017
Q1 		$31K Buy
3,391
+3,286
+3,130% +$28.9K ﹤0.01% 1018
2016
Q4 		$1K Sell
105
-2,007
-95% -$18.4K ﹤0.01% 3757
2016
Q3 		$24K Buy
2,112
+1,075
+104% +$12.5K ﹤0.01% 1521
2016
Q2 		$13K Sell
1,037
-243
-19% -$2.95K ﹤0.01% 2633
2016
Q1 		$13K Buy
1,280
+973
+317% +$11.4K ﹤0.01% 1739
2015
Q4 		$7K Buy
+307
New +$6.29K ﹤0.01% 2708
2015
Q3 		– Sell
-1,382
Closed -$31K – 5646
2015
Q2 		$31K Buy
1,382
+490
+55% +$12.1K ﹤0.01% 1755
2015
Q1 		$23K Buy
892
+872
+4,360% +$22.1K ﹤0.01% 2161
2014
Q4 		$0 Buy
+20
New +$410 ﹤0.01% 5539
2014
Q1 		– Sell
-4,102
Closed -$121K – 5563
2013
Q4 		$121K Buy
4,102
+3,902
+1,951% +$71.5K 0.02% 755
2013
Q3 		$3K Buy
+200
New +$3.71K ﹤0.01% 4062

Other funds holding OMED

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Tower Research Capital (TRC)'s OMED Position: Q4 2018 in Review

Tower Research Capital (TRC) sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q4 2018, closing a stake of 17,025 shares — an estimated $36K sold.

Tower Research Capital (TRC) first reported a position in OMED in Q3 2013 and held it in 16 quarters. The position peaked at $121K in Q4 2013. 42 funds tracked by Wall St. Rank hold OMED as of Q4 2018.

  • Tower Research Capital (TRC) reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 17,025 OncoMed Pharmaceuticals, Inc. shares in Q4 2018, an estimated $36K.
  • Tower Research Capital (TRC) first reported a position in OncoMed Pharmaceuticals, Inc. in Q3 2013 and held it in 16 quarters.
  • Tower Research Capital (TRC)'s OncoMed Pharmaceuticals, Inc. position peaked at $121K in Q4 2013.
  • 42 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q4 2018.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2018, filed 14 Feb 2019.